stockportfolio.pro
Stocks / ASMB vs STRO
ASMB vs STRO
Assembly Biosciences, Inc. and Sutro Biopharma, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Assembly Biosciences, Inc. (ASMB) | Sutro Biopharma, Inc. (STRO) | |
|---|---|---|
| Market cap | $0.4B | $0.4B |
| Revenue (latest FY) | $72.30M | $102.48M |
| Net income (latest FY) | $-6.12M | $-191.09M |
| Revenue growth (5y CAGR) | -1.8% | 19.1% |
| Net margin | -8.5% | -186.5% |
| Return on equity | -3.0% | 144.3% |
| P/E ratio | 275.2 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 1 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ASMB — free Open STRO — freeFrequently asked questions
Which is bigger, ASMB or STRO?
Sutro Biopharma, Inc. is larger by market capitalization — $0.4B versus $0.4B.
Which grows faster, ASMB or STRO?
Over the last five fiscal years, Sutro Biopharma, Inc. grew revenue faster — 19.1%/yr versus -1.8%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.